Vanda Pharmaceuticals Inc.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 06:06

Material Agreement (Form 8-K)

Item 1.01. Entry into a Material Definitive Agreement.
On November 16, 2026, Vanda Pharmaceuticals Inc. ("Vanda") entered into a Confidential Settlement and License Agreement (the "Settlement Agreement") with MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (together, "MSN"). The Settlement Agreement settles Vanda's patent infringement litigation against MSN, Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (the "Litigation"), in the U.S. District Court for the District of Delaware (the "Court"). In the Litigation, Vanda alleges that MSN's Abbreviated New Drug Application ("ANDA") infringes certain U.S. patents owned by Vanda that cover HETLIOZ LQ® (tasimelteon suspension, 4 mg/ml). The ANDA seeks approval to market a generic version of HETLIOZ LQ® in the U.S.
Under the Settlement Agreement, Vanda granted MSN a non-exclusive, royalty-free license to manufacture, import and market MSN's generic tasimelteon oral suspension in the U.S. on and after the License Effective Date (as defined below). MSN also received limited pre-launch rights to manufacture and import its product (beginning 180 days before the License Effective Date). It may also hold customer discussions and pricing and contracting discussions ahead of launch (beginning 30 days and 14 days before the License Effective Date, respectively).
The "License Effective Date" is in the first quarter of 2040, but MSN may be able to enter the market earlier under certain circumstances. These circumstances include the expiration of the licensed patents, a final court decision that the licensed patents are invalid, unenforceable or not infringed, and the launch of an authorized generic or a licensed generic version of HETLIOZ LQ®. They also include certain unlicensed third-party generic launches that Vanda does not enjoin or otherwise stop within a specified period. MSN may also supply its product before the License Effective Date if the FDA declares a drug shortage after Vanda voluntarily withdraws HETLIOZ LQ® for reasons other than safety or efficacy.
Vanda also agreed that if it later grants any other party certain more favorable terms, including with respect to market-entry timing or pre-launch rights, MSN will receive the benefit of those terms.
As required by law, Vanda and MSN have agreed to submit the Settlement Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. The Settlement Agreement provides for a full settlement of the claims asserted in the Litigation. It includes a release by Vanda of claims against MSN that were or could have been asserted in connection with MSN's generic tasimelteon oral suspension, HETLIOZ LQ® or the Litigation, arising before the effective date of the Settlement Agreement. MSN has acknowledged that the patents asserted in the Litigation are valid and enforceable with respect to its ANDA product. MSN has also agreed not to challenge the validity, enforceability or patentability of the licensed patents with respect to its ANDA product, subject to certain exceptions. The parties will file a stipulated order with the Court dismissing all claims in the Litigation. The parties will also submit to the Court, for its approval, a consent judgment and permanent injunction. The injunction would bar MSN from making, using, importing, offering for sale or selling its generic tasimelteon oral suspension except under a license from Vanda, and from inducing or contributing to such infringement by others.
The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the agreement. The agreement will be filed with the U.S. Securities and Exchange Commission as an exhibit to Vanda's Annual Report on Form 10-K for the fiscal year ending December 31, 2026.
Vanda Pharmaceuticals Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 20, 2026 at 12:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]